跳至主要内容
临床试验/JPRN-UMIN000002606
JPRN-UMIN000002606已完成2 期

HLA-haploidentical allogeneic stem cell transplantation for Adult T-cell leukemia/lymphoma (ATL/L) and refractory aggressive lymphoma - HLA-haploidentical allogeneic stem cell transplantation for ATL/L and refractory aggressive lymphoma

Hematology, Osaka City University, Graduate School of Medicine0 个研究点目标入组 17 人开始时间: 2009年10月10日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
17

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
15years-old 至 70years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1) Major organ dysfunction a) Total bilirubin: >= 2.0mg/dl b) Serum creatinine: >= 2.0mg/dl c) Ejection fraction: < 50 % d) Pulmonary function test: %VC <40%, FEV1.0% <50% or SaO2 <90% on room air e) AST or ALT >= 3 x UNL 2) Uncontrolled active infection 3) Uncontrolled CNS invasion 4) Poorly controlled insulin-treated diabetes mellitus 5) Poorly controlled hypertension 6) Patients with a severe complication including heart failure, coronary failure, acute myocardial infarction within the last 3 months, liver cirrhosis and interstitial pneumonia 7) Pregnant, nursing or possible fertile woman 8) Patients with mental disorder or neurological disorder who are likely to unable to participate in the study 9) A history of hypersensitivity or allergy to any drugs in conditioning regimen of this transplant 10) HIV antibody positivity 11) Patients with history of administration of mogamulizumab 12) No indication for this study judged by physician in charge. (Note: HBs antigen positivity and HCV antibody positivity is not excluded.)

研究者

发起方
Hematology, Osaka City University, Graduate School of Medicine

相似试验

已完成
不适用
HLA-haploidentical allogeneic stem cell transplantation for refractory hematopoietic diseasesAcute myeloid leukemia(AML) Acute lymphoblastic leukemia (ALL) Secondary acute myelogenous leukemia Chronic myeloid leukemia (CML) Myelodysplastic syndrome (MDS)
JPRN-UMIN000002069Hematology, Osaka City University, Graduate School of Medicine17
已完成
2 期
HLA-haploidentical allogeneic stem cell transplantation for refractory hematopoietic malignancies (OCU13-3)Acute myeloid leukemia(AML) Acute lymphoblastic leukemia (ALL) Chronic myeloid leukemia (CML) Myelodysplastic syndrome (MDS)
JPRN-UMIN000011293Osaka City University35
已完成
不适用
Allogeneic hematopoietic stem cell transplantation for elderly patients
JPRN-UMIN000017744nivesity of Tokyo Hospital, Department of Hematology and Oncology50
已完成
不适用
Allogeneic hematopoietic stem cell transplantation (HSCT) from HLA-haploidentical related donor using reduced dose of posttransplantation high-dose cyclophosphamide (PTCy) for poor prognosis or refractory hematological malignancies (OCU16-2)Acute myeloid leukemia(AML) Acute lymphoblastic leukemia(ALL) Acute leukemias of ambiguous lineage Myelodysplastic syndrome(MDS) Chronic myeloid leukemia(CML) Adult T-cell leukemia/lymphoma(ATLL) Malignant lymphoma(ML)
JPRN-UMIN000026028Osaka City University33
招募中
2 期
Allogeneic hematopoietic stem cell transplantation from HLA6/8-4/8 matched related donor for poor prognostic or refractory hematologic malignancy and solid tumor - Ibaraki Children&#39;s Hospital phase II studyAcute leukemia, malignant lymphoma, and solid tumor
JPRN-UMIN000027010Ibaraki Children&#39;s Hospital30